ChatGPT SearchJun 22, 2026
Encelto became the first approved treatment for idiopathic MacTel type 2.
Loading…
ENCELTO is an encapsulated cell-based gene therapy for adults with idiopathic macular telangiectasia type 2 (MacTel), a retinal disease causing progressive vision loss. It consists of a small capsule implanted in the eye that continuously releases a protein to protect photoreceptors and slow disease progression.
AI named ENCELTO from November 2025 to June 2026.
Question: What are the latest affordable advancements in biopharma for treating rare diseases?
ChatGPT SearchJun 22, 2026
Encelto became the first approved treatment for idiopathic MacTel type 2.
None of these answers cited encelto.com. AI leaned on fda.gov, labiotech.eu, and reuters.com.
encelto.com 0%Other sites 100%
Excerpts where ENCELTO appeared in the AI's answer
Encelto became the first approved treatment for idiopathic MacTel type 2.
